Pharmafile Logo

dacomitinib

AstraZeneca AZ

AZ’s immuno-oncology combo fails another lung cancer trial

Latest failure casts doubt on company’s CTLA4 drug

- PMLiVE

Merck’s Keytruda meets survival challenge in NSCLC

Data showed that almost 70% of patients on the combo were still alive after 12 months

- PMLiVE

AZ makes case for first-line Tagrisso therapy in lung cancer

Data shows the drug improved PFS versus older EGFR inhibitors including Roche’s Tarceva

- PMLiVE

AZ taps Ionis for another drug, this time in NASH

Will acquire the US pharma group’s antisense drug in a deal valued up to $330m

- PMLiVE

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

Interim data suggested there was no improvement on disease-free survival compared to placebo

- PMLiVE

AbbVie’s upadacitinib aces phase III trial

Arthritis drug outperformed both placebo and Humira in the study

- PMLiVE

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Both EU and US regulatory advisors are currently assessing the drug

How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market

Our client was developing a new drug aimed at first line NSCLC patients. Ahead of its launch they wanted to assess likely uptake in an already fragmented market space led...

Research Partnership

Roche Basel Switzerland

Another Tecentriq win for Roche as Avastin combo boosts survival

The Swiss pharma group reported a 38% improvement in PFS in NSCLC patients

- PMLiVE

AZ finally gets EU nod for Veltassa rival Lokelma

And expects a US FDA verdict for the hyperkalaemia treatment later this year

- PMLiVE

GSK joins Reckitt in passing on Pfizer’s consumer health unit

The healthcare business doesn’t meet GSK’s criteria for returns, says Walmsley

- PMLiVE

New data could put Roche’s Tecentriq first in squamous lung cancer

NSCLC patients on the drug saw a reduced risk of disease progression

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links